{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T23:40:59Z","timestamp":1779925259665,"version":"3.53.1"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["Investment 051835)"],"award-info":[{"award-number":["Investment 051835)"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>There is insufficient data to inform the management of dolutegravir failure, with the WHO and various countries adopting different approaches, underscoring the need for an evidence-based management approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The Ndovu study is a large multi-country cohort, with a nested randomised controlled trial (RCT), enrolling 6,600 people living with HIV (PLWH) with viral load (VL) of \u22651000 copies\/ml after at least 6 months of dolutegravir. Participants aged\u2009\u2265\u20091 year, including pregnant women, will be followed up for 12 months with enhanced adherence counselling (EAC) provided monthly. Viral load (VL) testing will be conducted every 3 months and drug resistance testing conducted if VL\u2009\u2265\u2009200 copies\/ml. Three hundred and sixty-two participants aged \u226515 years and 30 participants aged 3\u201314 years with major dolutegravir-associated drug resistant mutations (DRMs) will be enrolled into the RCT and randomised to switch to ritonavir boosted darunavir (DRV\/r) or continue with dolutegravir with follow-up for 12 months. VL will be measured at 1, 3, 6 and 12 months and tenofovir levels assessed on dried blood spots at month 1 and month 6.<\/jats:p>\n                    <jats:p>The primary outcome of the cohort is the proportion of participants achieving viral load &lt;200 copies\/ml by month 12 and the primary endpoint of the RCT is viral load &lt;200copies\/ml at 6 months using a modified FDA snap shot algorithm. Secondary endpoints are DRM patterns associated with non-suppression, level of adherence associated with suppression as well as participant and provider experiences of staying on DTG versus switching to DRV\/r.<\/jats:p>\n                    <jats:p>The RCT primary efficacy analysis will be conducted on the Intent-to-Treat Exposed (ITT-E) population and will compare the difference in the proportion of participants with viral load &lt;200 copies\/ml 6 months after randomisation between the treatment arms stratified by the randomisation stratification factors.<\/jats:p>\n                    <jats:p>This study is registered at ClinicalTrials.gov, NCT06762054 (cohort) and NCT06747507 (RCT) and enrollment into the cohort started in March 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The Ndovu study will address critical gaps in the management of DTG failure including the emergence, determinants and implications of DTG resistance. Further, it will evaluate the optimal ART regimens to use in the setting of DTG resistance in adults and children.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0330792","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:42:01Z","timestamp":1773423721000},"page":"e0330792","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["The dolutegravir failure cohort: A multi-country longitudinal cohort with a randomised clinical trial of continued dolutegravir versus switch to darunavir in people with viraemia while on dolutegravir in Sub-Saharan Africa (The Ndovu Study) protocol"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4632-8792","authenticated-orcid":true,"given":"Loice Achieng","family":"Ombajo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Nkuranga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6443-1748","authenticated-orcid":true,"given":"Jeremy","family":"Penner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily Wangui","family":"Kamau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nalia","family":"Ismael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8754-2755","authenticated-orcid":true,"given":"Patricia","family":"Munseri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Ayakaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklaus","family":"Labhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dalton","family":"Wamalwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0474-3317","authenticated-orcid":true,"given":"Patricia","family":"Ramgi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel Matavele","family":"Chissumba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4793-9296","authenticated-orcid":true,"given":"James","family":"Wagude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Bakari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Omodi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"Otieno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Abuogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9893-5856","authenticated-orcid":true,"given":"Rena","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Opondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Grint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6883-267X","authenticated-orcid":true,"given":"Leonard","family":"King\u2019wara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AnneMarie","family":"Macharia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Mulwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Amoth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Ndovu study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"pone.0330792.ref001","volume-title":"The state of HIV treatment, testing, and prevention in low- and middle-income countries; HIV market report 2023","year":"2023"},{"key":"pone.0330792.ref002","volume-title":"Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach","year":"2021"},{"key":"pone.0330792.ref003","volume-title":"Kenya HIV prevention and treatment guidelines","year":"2022"},{"key":"pone.0330792.ref004","author":"Ministry of Health Botswana","journal-title":"The Botswana 2023 integrated HIV clinical care guidelines"},{"key":"pone.0330792.ref005","author":"Rep\u00fablica de Mo\u00e7ambique Menist\u00e9rio da Sa\u00fade","year":"2023","journal-title":"Gui\u00e3o de cuidados do HIV do Adulto, Adolescente Gr\u00e1vida, Lactante e Crian\u00e7a"},{"key":"pone.0330792.ref006","volume-title":"National Guidelines for the Management of HIV and AIDS: 7th Edition","author":"The United Republic of Tanzania, Ministry of Health, Community Development, Gender, Elderly, and Children","year":"2019"},{"key":"pone.0330792.ref007","volume-title":"2023 ART Clinical Guidelines for the Management of HIV in Adults, Pregnancy and Breastfeeding, Adolescents, Children, Infants and Neonates","author":"Department of Health of the Republic of South Africa","year":"2023"},{"key":"pone.0330792.ref008","volume-title":"National Guidelines on the Use of Antiretroviral Therapy for HIV Treatment and Prevention, 6th Edition","author":"Ministry of Health of Lesotho","year":"2022"},{"key":"pone.0330792.ref009","volume-title":"Zambia Consolidated Guidelines for Treatment and Prevention of HIV Infection, May 2022 Version","author":"Ministry of Health of the Republic of Zambia","year":"2022"},{"issue":"9","key":"pone.0330792.ref010","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1093\/cid\/ciu046","article-title":"Lower pill burden and once-daily antiretroviral treatment regimens for HIV infection: A meta-analysis of randomized controlled trials","volume":"58","author":"JB Nachega","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"3","key":"pone.0330792.ref011","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3390\/v16030399","article-title":"Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review","volume":"16","author":"C Chu","year":"2024","journal-title":"Viruses"},{"key":"pone.0330792.ref012","volume-title":"Emerging dolutegravir resistance among children being investigated for treatment failure in Malawi","author":"G Bello","year":"2024"},{"key":"pone.0330792.ref013","author":"N Ismael","year":"2023","journal-title":"HIV drug resistance profile in clients experiencing treatment failure after the transition to dolutegravir-based first-line antiretroviral treatment in Mozambique"},{"key":"pone.0330792.ref014","volume-title":"Dolugetravir resistance among ART-experienced viremic patients in Kenya receiving DTG-based ART","author":"L Kingwara","year":"2024"},{"key":"pone.0330792.ref015","author":"WHO","year":"2024","journal-title":"HIV drug resistance brief report"},{"issue":"5","key":"pone.0330792.ref016","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1093\/cid\/ciae185","article-title":"Emergence of acquired dolutegravir resistance in treatment-experienced people with HIV in Lesotho","volume":"79","author":"N Tschumi","year":"2024","journal-title":"Clin Infect Dis"},{"key":"pone.0330792.ref017","article-title":"Predicting emergent dolutegravir resistance in South Africa: a modelling study","author":"T Loosli","year":"2024","journal-title":"medRxiv preprint"},{"key":"pone.0330792.ref018","doi-asserted-by":"crossref","DOI":"10.1097\/QAD.0000000000003082","article-title":"Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era","volume":"35","author":"SM McCluskey","year":"2021","journal-title":"AIDS"},{"issue":"11","key":"pone.0330792.ref019","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(23)00228-X","article-title":"HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis","volume":"10","author":"T Loosli","year":"2023","journal-title":"Lancet HIV"},{"key":"pone.0330792.ref020","unstructured":"Stanford HIV Drug Resistance Database. https:\/\/hivdb.stanford.edu\/"},{"issue":"9","key":"pone.0330792.ref021","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.3390\/v15091932","article-title":"Treatment Emergent Dolutegravir Resistance Mutations in Individuals Na\u00efve to HIV-1 Integrase Inhibitors: A Rapid Scoping Review","volume":"15","author":"K Tao","year":"2023","journal-title":"Viruses"},{"issue":"4","key":"pone.0330792.ref022","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1056\/NEJMoa2101609","article-title":"Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV","volume":"385","author":"NI Paton","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0330792.ref023","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/v16010029","article-title":"Virological Findings and Treatment Outcomes of Cases That Developed Dolutegravir Resistance in Malawi\u2019s National HIV Treatment Program","volume":"16","author":"H Kanise","year":"2023","journal-title":"Viruses"},{"issue":"8","key":"pone.0330792.ref024","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(24)00183-9","article-title":"Resistance-informed versus empirical management of viraemia in children and adolescents with HIV in Lesotho and Tanzania (GIVE MOVE trial): a multisite, open-label randomised controlled trial","volume":"12","author":"JA Brown","year":"2024","journal-title":"Lancet Glob Health"},{"issue":"1","key":"pone.0330792.ref025","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01710-17","article-title":"Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy","volume":"62","author":"PL Anderson","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"pone.0330792.ref026","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1089\/aid.2012.0089","article-title":"Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure","volume":"29","author":"JR Castillo-Mancilla","year":"2013","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"7","key":"pone.0330792.ref027","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/QAD.0000000000003185","article-title":"Tenofovir diphosphate in dried blood spots predicts future viremia in persons with HIV taking antiretroviral therapy in South Africa","volume":"36","author":"L Jennings","year":"2022","journal-title":"AIDS"},{"issue":"4","key":"pone.0330792.ref028","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/QAI.0000000000003198","article-title":"Comparing Predictive Ability of Two Objective Adherence Measures in a Community-Based Cohort on Antiretroviral Therapy in South Africa: Tenofovir Diphosphate Concentrations and Electronic Adherence Monitors","volume":"93","author":"L Jennings","year":"2023","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"pone.0330792.ref029","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/infdis\/jiz144","article-title":"Predictive Value of Tenofovir Diphosphate in Dried Blood Spots for Future Viremia in Persons Living With HIV","volume":"220","author":"M Morrow","year":"2019","journal-title":"J Infect Dis"},{"issue":"1","key":"pone.0330792.ref030","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12981-023-00552-w","article-title":"Tenofovir diphosphate in dried blood spots and HIV-1 resistance in South Africa","volume":"20","author":"Y Singh","year":"2023","journal-title":"AIDS Res Ther"},{"issue":"13","key":"pone.0330792.ref031","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.3390\/diagnostics13132209","article-title":"Advancing HIV Drug Resistance Technologies and Strategies: Insights from South Africa\u2019s Experience and Future Directions for Resource-Limited Settings","volume":"13","author":"K Steegen","year":"2023","journal-title":"Diagnostics (Basel)"},{"issue":"4","key":"pone.0330792.ref032","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s40121-021-00522-7","article-title":"HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review","volume":"10","author":"R Patel","year":"2021","journal-title":"Infect Dis Ther"},{"key":"pone.0330792.ref033","article-title":"Dolutegravir Resistance in Mozambique: Insights from a Programmatic HIV Resistance Testing Intervention in a Highly ART Experienced Cohort","author":"M Ruano","journal-title":"Preprint"},{"issue":"1","key":"pone.0330792.ref034","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1001\/jama.2022.22246","article-title":"Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel","volume":"329","author":"RT Gandhi","year":"2023","journal-title":"JAMA"},{"issue":"5","key":"pone.0330792.ref035","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3018(25)00074-8","article-title":"Impact of an international HIV funding crisis on HIV infections and mortality in low-income and middle-income countries: a modelling study","volume":"12","author":"DT Brink","year":"2025","journal-title":"Lancet HIV"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0330792","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T17:42:11Z","timestamp":1773423731000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0330792"}},"subtitle":[],"editor":[{"given":"Sarah","family":"Nanzigu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":35,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0330792","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]}}}